GENE THERAPY READY
LIVE

Serial Number

90673637

Owner

ADVARRA, INC.

Attorney

Andrew J. Ferren

First Use Date

Jan 19, 2021

Filing Date

Apr 27, 2021

Add to watchlist:

No watchlists yet
View on USPTO

GENE THERAPY READY Trademark

Serial Number: 90673637 • Registration: 6927368

GENE THERAPY READY is a trademark filed by ADVARRA, INC. on April 27, 2021. The trademark is classified under Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

ADVARRA, INC. (36 trademarks)

Columbia, MD 21044

Entity Type: 03

Trademark Details

Filing Date

April 27, 2021

Registration Date

December 20, 2022

First Use Anywhere

January 19, 2021

First Use in Commerce

January 19, 2021

Published for Opposition

October 4, 2022

Goods & Services

organizing and administering a network of research sites, namely, business management in the field of clinical trials, specifically, providing governmental registration assistance in the nature of regulatory submission management on behalf of research sites that conduct gene therapy and vaccine research to assist them with clinical research and clinical trials; providing institutional biosafety committee services, namely, providing independent review and oversight of clinical trials involving genetically engineered gene therapy and vaccine research for business purposes

Providing institutional biosafety committee services, namely, providing independent review and oversight of clinical trials involving genetically engineered gene therapy and vaccine research, specifically, reviewing research protocols and related information to ensure protection of the rights and welfare of human subjects of research; assessing the readiness of research sites to conduct gene therapy and vaccine research, namely, reviewing standards and practices to assure compliance with laws and regulations in the field of clinical trials involving human subjects

Providing institutional biosafety committee services, namely, providing independent review and oversight of clinical trials involving genetically engineered gene therapy and vaccine research, specifically, evaluating research sites involved in gene therapy and vaccine research clinical trials to determine whether the organizations conform to an established accreditation standard; assessing the readiness of research sites to conduct gene therapy and vaccine research, namely, testing, analysis, and evaluation of gene therapy and vaccine research service providers to determine conformity with established accreditation standards

Filing History

ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jan 25, 2023 ASCK
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 20, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 20, 2022 R.PR
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Nov 2, 2022 ASCK
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 4, 2022 NPUB
PUBLISHED FOR OPPOSITION
Oct 4, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 14, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 29, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 29, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 29, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 29, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 29, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 29, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 29, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 29, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 11, 2022 GNRN
NON-FINAL ACTION E-MAILED
Feb 11, 2022 GNRT
NON-FINAL ACTION WRITTEN
Feb 11, 2022 CNRT
ASSIGNED TO EXAMINER
Dec 23, 2021 DOCK
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 24, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 24, 2021 TCCA
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 24, 2021 COAR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 2, 2021 NWOS
NEW APPLICATION ENTERED
Apr 30, 2021 NWAP